A Phase 1 interventional study of VC004 and Itraconazole and VC004 and rifampicin in Locally Advanced or Metastatic Solid Tumor, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-10.
Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.
Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 238th largest by enrollment of the 401 interventional ones that give a count, is one of 45 that started in 2024, is one of 93 in phase 1, and was the 341st registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.
Browse Neoplasm Metastasis studies →222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–75
Nanjing Medical University · Sites in China
Ages 18–80
Genovn Therapeutics (Suzhou) Co., Ltd. · Sites in China
Ages 18–70
Fudan University · Sites in China
Ages 18–75
Taizhou Mabtech Pharmaceutical Co.,Ltd · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
485 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 141 · Phase 2 169 · Phase 3 85 · Phase 4 13
First in 2003; this study’s year is marked. 45 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is above the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 90 across the 401 interventional studies, 180 across the 83 observational. Of the 103 that completed or were terminated, 27 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
171 of 485 have an industry lead sponsor. The 10 most frequent:
Jiangsu vcare pharmaceutical technology co., LTD is the lead sponsor of 35 studies on the registry; 12 are open to participants now.
Jiangsu vcare pharmaceutical technology co., LTD has 3 studies filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
81 of the studies in Neoplasm Metastasis with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT05794971Phase 3Sun Yat-sen UniversityRegorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases | 2027-03-31 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT06961188Phase 3Changchun GeneScience Pharmaceutical Co., Ltd.Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis | 2027-06-30 |
Add all 81 to your calendar (.ics) → With an account.
Among the 485 studies in Neoplasm Metastasis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will adopt a Single-center, Single-arm, Open, Fixed Sequence design to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: VC004 and Itraconazole
Drug: VC004 and rifampicin
Drug pages: Eratrectinib · Itraconazole
A single dose of VC004 was administered in the period 1. and a single dose of VC004 and Itraconazole coadministration in the period 2.
Drug pages: Eratrectinib · Rifampin
A single dose of VC004 was administered in the period 1. and a single dose of VC004 and rifampicin coadministration in the period 2.
Maximum Observed Plasma Concentration (Cmax)
Maximum Observed Plasma Concentration (Cmax)
Time frame: Day1-Day16
Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC)
Time frame: Day1-Day16
Ran from Sep 2024 to primary completion in Oct 2024, 1 month.
Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 1 month is below that.
Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Eratrectinib · Itraconazole · Rifampin
Jiangsu vcare pharmaceutical technology co., LTD →